Page 387 - ESHRE2019
P. 387
Tuesday, 25 June 2019:
09:50 - 10:50
Product/Educational Theatre ObsEva
Increasing IVF Success with Nolasiban, a New, Oral, Oxytocin Receptor Antagonist
Chair: Juan Garcia Velasco (Spain) Chair: Ernest Loumaye (Switzerland)
Live Birth and Infant Follow-up: Results from a Nolasiban Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial in IVF
Georg Griesinger (Germany)
Reproductive Safety Studies Supporting the Use of Nolasiban in IVF
Oliver Pohl (Switzerland)
The Cost of IVF, Looking Beyond the Obvious
Ben W. Mol (Australia)
COMPANY SYMPOSIA I VIENNA, AUSTRIA – 23 TO 26 JUNE 2019
387
COMPANY SYMPOSIA
